Can cisplatin and pemetrexed cause constipation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 4, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Cisplatin and Pemetrexed Cause Constipation?

Yes, cisplatin and pemetrexed can cause constipation, though it is not among the most common or severe toxicities associated with this combination regimen.

Evidence from Clinical Trials

The combination of cisplatin and pemetrexed does list constipation as a documented adverse event, though it occurs at relatively low rates:

  • In a Japanese safety study of bevacizumab plus cisplatin/pemetrexed in malignant pleural mesothelioma patients, constipation (grade 1/2 only) occurred in 71.4% of patients, making it one of the more common gastrointestinal side effects 1.

  • In a phase III trial comparing docetaxel plus cisplatin regimens for non-small cell lung cancer, grade 3 constipation occurred in 1% of patients and grade 4 constipation in 1% of patients receiving cisplatin-based therapy 2.

More Common Gastrointestinal Toxicities to Anticipate

While constipation can occur, the predominant gastrointestinal toxicities with cisplatin/pemetrexed are nausea, vomiting, diarrhea, dehydration, and stomatitis, which are significantly more frequent and clinically relevant:

  • Nausea, vomiting, fatigue, diarrhea, dehydration, and stomatitis are significantly higher in the pemetrexed/cisplatin arm compared to cisplatin alone 2.

  • In the Japanese study, nausea occurred in 85.7% of patients (grade 1/2 only) 1.

  • The Thorax guidelines specifically note that fatigue, dehydration, and stomatitis are significantly more common with the pemetrexed/cisplatin combination 3.

Clinical Management Approach

When counseling patients about this regimen, prioritize discussion of the more common and severe toxicities:

  • Hematologic toxicities (neutropenia, anemia, thrombocytopenia) are the most clinically significant, with grade 3-4 neutropenia occurring in 15.1% of patients 2.

  • Overall, 62% of patients receiving pemetrexed plus cisplatin experience grade 3-4 adverse events 3.

  • Prophylactic antiemetics are essential, as reflected in the cost analyses showing antiemetic costs of $653.40 per month for cisplatin-based regimens 2.

Common Pitfall

Do not overlook the mandatory vitamin supplementation requirements (folic acid and vitamin B12) when prescribing pemetrexed, as these reduce hematologic toxicity 4, 3. While managing constipation if it occurs, focus monitoring efforts on the more frequent and severe toxicities: myelosuppression, nausea/vomiting, and fatigue.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Cisplatin and Pemetrexed Chemotherapy Side Effects

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Pemetrexed Treatment Guidelines for Cancer

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.